News

Article

Avantor Makes Multi-Year Investment in Hydration Capabilities for Biologics Production

Avantor plans to address rising global demand for biologics with their investment in hydration capabilities.

Avantor announced a multi-year investment into its global hydration capabilities on Aug. 31, 2021 that includes a recently completed expansion to its facility in Gliwice, Poland, as well as a multi-stage expansion of its facility in Aurora, Ohio, that is expected to be completed by mid-2022.

The facility investments in Gliwice and Aurora will add to Avantor’s existing water for injection-quality (WFI) buffer manufacturing capabilities. The new equipment will provide enhanced capabilities and capacity to formulate and fill WFI-based hydration solutions, according to a company press release.

"Buffer management is a key area where biopharma manufacturers can save time while reducing risk and costs,” said Ger Brophy, executive vice-president of Biopharma Production at Avantor, in the press release. “This recent investment in our global hydration offering allows us to strengthen our [C]GMP [current good manufacturing practices] chemical manufacturing in Europe and the United States."

Source: Avantor

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content